BUDAPEST, October 16, 2017 /PRNewswire/ --
Darholding is pleased to announce that one of its portfolio companies, Nuformix, will list on the London Stock Exchange via a reverse takeover of Levrett PLC. Darholding was one of the founders, along with other private and institutional shareholders, in Nuformix, a company with proprietary co-crystallization technologies. Based in Cambridge, UK, Nuformix was founded in 2009 to unlock the therapeutic potential of approved drugs with lead programs in oncology supportive care and fibrosis. After successful early studies Nuformix sought a strategic partner and investor to take its programs further, which it found in the form of Levrett plc. Under the terms of the reverse takeover, announced on 15 September 2017, Levrett and Nuformix will merge and at the same time investors will place GBP 2.4 million of new capital in support of further developing the clinical studies.
Darholding is a Budapest based upstream innovation incubating organization with interests in scientific research in pharmaceuticals, agrochemicals, fine chemicals, flavors and fragrances, laboratory instrumentation and chemistry development in Space. It operates globally through a network of companies who are all pioneers in their chosen field.
Contact: Gergely Darvas, Investment Director, Darholding Ltd [email protected] +36-20-9494-300
SOURCE Darholding Ltd
Advertisement
Darholding is pleased to announce that one of its portfolio companies, Nuformix, will list on the London Stock Exchange via a reverse takeover of Levrett PLC. Darholding was one of the founders, along with other private and institutional shareholders, in Nuformix, a company with proprietary co-crystallization technologies. Based in Cambridge, UK, Nuformix was founded in 2009 to unlock the therapeutic potential of approved drugs with lead programs in oncology supportive care and fibrosis. After successful early studies Nuformix sought a strategic partner and investor to take its programs further, which it found in the form of Levrett plc. Under the terms of the reverse takeover, announced on 15 September 2017, Levrett and Nuformix will merge and at the same time investors will place GBP 2.4 million of new capital in support of further developing the clinical studies.
Advertisement
Darholding is a Budapest based upstream innovation incubating organization with interests in scientific research in pharmaceuticals, agrochemicals, fine chemicals, flavors and fragrances, laboratory instrumentation and chemistry development in Space. It operates globally through a network of companies who are all pioneers in their chosen field.
Contact: Gergely Darvas, Investment Director, Darholding Ltd [email protected] +36-20-9494-300
SOURCE Darholding Ltd
